Novo Nordisk has filed a lawsuit against Eli Lilly, alleging that television advertisements for Zepbound and Mounjaro make misleading comparisons with Wegovy and Ozempic. The suit claims Lilly's ads cite an outdated study showing Zepbound users lost an average of 50 pounds versus 33 pounds on Wegovy, while a newer, higher dose of Wegovy approved in March and launched in April increased average weight loss to 47 pounds. Novo Nordisk is seeking a permanent injunction to pull the ads, a corrective campaign, and recovery of lost profits. The global obesity drug market reached $66 billion in 2025 and is projected to hit $120 billion by 2030, with Eli Lilly holding about 60% of the U.S. market as of February.
Eli Lilly and CompanyNovo Nordisk sues Eli Lilly over misleading ads, seeking injunction and corrective campaign.
Novo Nordisk A/SNovo Nordisk files lawsuit alleging Eli Lilly's ads are deceptive, potentially harming Lilly's market position.